Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491046 | ||
| 003 | CHVBK | ||
| 005 | 20210128100508.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150601xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0733-z |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0733-z | ||
| 245 | 0 | 0 | |a Phase I trial of neoadjuvant preoperative chemotherapy with S-1, oxaliplatin, and bevacizumab plus radiation in patients with locally advanced rectal cancer |h [Elektronische Daten] |c [Hirohiko Sato, Mitsuo Shimada, Nobuhiro Kurita, Takashi Iwata, Kozo Yoshikawa, Jun Higashigima, Motoya Chikakio, Hideya Kashihara, Chie Takasu, Noriko Matsumoto, Shozo Eto] |
| 520 | 3 | |a Background: This phase I study was performed to determine the maximum tolerated dose (MTD), recommended dose (RD), and dose-limiting toxicities (DLTs) of oxaliplatin combined with preoperative chemoradiotherapy with S-1, oxaliplatin, and bevacizumab in locally advanced rectal cancer. Methods: Eligible patients had a newly diagnosed clinical stage T1-4 N0-3 M0 rectal adenocarcinoma within 12cm of the anal verge suitable for curative resection. Conformal radiation therapy was given (4 fields, 2Gy daily fractions, 5days/week, total dose 40Gy) with concurrent S-1 (80mg/m2/day orally, days 1-5, 8-12, 15-19, and 22-26), bevacizumab (90min continuous intravenous infusion at 5mg/kg, days 1 and 15), and oxaliplatin (120min continuous intravenous infusion, days 1, 8, 15, and 22). The initial oxaliplatin dose (40mg/m2/day) was gradually increased to determine the MTD and RD. Surgery was performed 6weeks after completion of preoperative chemoradiotherapy. Results: 11 patients were enrolled. The MTD of oxaliplatin was considered to be 60mg/m2, because three of five patients developed DLTs such as diarrhea and hives. The recommended dose of oxaliplatin was set at 50mg/m2. Of the patients who received oxaliplatin at≤RD, 5 (83.3%) had a clinical response [four pathological responses and one pathological complete response (Grade 3)]. Conclusions: With this new regimen, the MTD of oxaliplatin was 60mg/m2, and the RD for phase II studies was 50mg/m2. This new regimen appears to provide worthwhile outcomes for locally advanced rectal cancer and merits a phase II study. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Bevacizumab |2 nationallicence | |
| 690 | 7 | |a Neoadjuvant chemoradiotherapy |2 nationallicence | |
| 690 | 7 | |a Oxaliplatin |2 nationallicence | |
| 690 | 7 | |a Phase I study |2 nationallicence | |
| 690 | 7 | |a Rectal cancer |2 nationallicence | |
| 690 | 7 | |a S-1 |2 nationallicence | |
| 700 | 1 | |a Sato |D Hirohiko |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Shimada |D Mitsuo |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Kurita |D Nobuhiro |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Iwata |D Takashi |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Yoshikawa |D Kozo |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Higashigima |D Jun |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Chikakio |D Motoya |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Kashihara |D Hideya |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Takasu |D Chie |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Matsumoto |D Noriko |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 700 | 1 | |a Eto |D Shozo |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 543-548 |x 1341-9625 |q 20:3<543 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0733-z |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0733-z |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sato |D Hirohiko |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Shimada |D Mitsuo |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kurita |D Nobuhiro |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Iwata |D Takashi |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Yoshikawa |D Kozo |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Higashigima |D Jun |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Chikakio |D Motoya |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kashihara |D Hideya |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takasu |D Chie |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Matsumoto |D Noriko |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Eto |D Shozo |u Department of Surgery, Institute of Health Biosciences, The University of Tokushima, 3-18-15 Kuramoto-cho, 770-8503, Tokushima, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/3(2015-06-01), 543-548 |x 1341-9625 |q 20:3<543 |1 2015 |2 20 |o 10147 | ||